A newly developed solution enhances thirty-hour preservation in a canine lung transplantation model

J Thorac Cardiovasc Surg. 1996 Sep;112(3):569-76. doi: 10.1016/S0022-5223(96)70037-5.

Abstract

Ischemia and reperfusion cause the production of oxygen free radicals. These damage grafts or disrupt normal vascular homeostatic mechanisms, with a parallel reduction in endothelial nitric oxide and adenosine 3',5'-cyclic monophosphate levels. We hypothesized that lung preservation failure may be related to these events. To improve lung preservation, we prepared a new ET-Kyoto solution, which contains N-acetylcysteine (a radical scavenger), nitroglycerin (to elevate the nitric oxide level), and dibutyryl adenosine 3',5'-cyclic monophosphate (to elevate the adenosine 3',5'-cyclic monophosphate level) and examined its efficacy in a canine single-lung transplantation model. Lungs were flushed with new ET-Kyoto solution (group I, n = 9), basal ET-Kyoto solution (group II, n = 6), basal ET-Kyoto solution plus ethanol and propylene glycol (solvents of nitroglycerin; group III, n = 6), or low-potassium dextran glucose solution (group IV, n = 6), and stored at 4 degrees C for 30 hours. After left single-lung transplantation, the right main bronchus and right pulmonary artery were ligated and the functions of the transplanted lung were assessed for 6 hours. Arterial oxygen tension was significantly higher in group I than in groups II, III, and IV (p < 0.05). Peak inspiratory pressure and wet-to-dry lung weight ratio were significantly lower in group I than in groups II and IV (p < 0.01). Histologic and ultrastructural studies showed better preservation in group I than in groups II, III, and IV. We conclude that the new ET-Kyoto solution provides enhanced 30-hour lung preservation.

MeSH terms

  • Animals
  • Cryopreservation
  • Cryoprotective Agents / administration & dosage
  • Cryoprotective Agents / therapeutic use
  • Cyclic AMP / metabolism
  • Dextrans / administration & dosage
  • Dextrans / therapeutic use
  • Dogs
  • Endothelium, Vascular / metabolism
  • Ethanol / administration & dosage
  • Ethanol / therapeutic use
  • Free Radicals / metabolism
  • Gluconates / administration & dosage
  • Gluconates / therapeutic use*
  • Glucose / administration & dosage
  • Glucose / therapeutic use
  • Homeostasis
  • Hydroxyethyl Starch Derivatives / administration & dosage
  • Hydroxyethyl Starch Derivatives / therapeutic use*
  • Inhalation
  • Ischemia / metabolism
  • Lung Transplantation* / pathology
  • Lung Transplantation* / physiology
  • Nitric Oxide / metabolism
  • Organ Preservation*
  • Organ Size
  • Oxygen / blood
  • Phosphates / administration & dosage
  • Phosphates / therapeutic use*
  • Potassium / administration & dosage
  • Potassium / therapeutic use
  • Pressure
  • Propylene Glycol
  • Propylene Glycols / administration & dosage
  • Propylene Glycols / therapeutic use
  • Pulmonary Ventilation
  • Reactive Oxygen Species / metabolism
  • Reperfusion Injury / metabolism
  • Solutions
  • Time Factors
  • Trehalose / administration & dosage
  • Trehalose / therapeutic use*

Substances

  • Cryoprotective Agents
  • Dextrans
  • ET-Kyoto solution
  • Free Radicals
  • Gluconates
  • Hydroxyethyl Starch Derivatives
  • Phosphates
  • Propylene Glycols
  • Reactive Oxygen Species
  • Solutions
  • Nitric Oxide
  • Ethanol
  • Propylene Glycol
  • Trehalose
  • Cyclic AMP
  • Glucose
  • Potassium
  • Oxygen